Labigat

Ranolazine, the active ingredient in Labigat, is an antianginal agent presented as an oral formulation for oral use. It is used to treat chronic stable angina and other forms of angina pectoris in adults. GNH USA supplies Labigat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Labigat (ranolazine) is employed in the management of chronic stable angina and related ischemic heart conditions. - Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance. - Angina pectoris: alleviates chest pain associated with myocardial ischemia. - Ischemic heart disease: contributes to overall symptom control when conventional therapies are insufficient.

Ranolazine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: transient light‑headedness reported by some patients. - Nausea: mild to moderate gastrointestinal upset. - Constipation: reduced bowel movements during therapy.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to ventricular arrhythmias. - Severe hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypersensitivity reactions: rash, angioedema, or anaphylaxis in rare cases.

When prescribing Labigat, clinicians should consider several safety measures. - Renal impairment: adjust dose or monitor renal function closely. - Hepatic impairment: use caution and consider dose reduction. - QT prolongation risk: obtain baseline ECG and monitor periodically. - Concomitant strong CYP3A4 inhibitors: avoid or adjust therapy. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ranolazine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ranolazine levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Other QT‑prolonging agents (e.g., sotalol, amiodarone): additive risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Digoxin: may increase serum concentrations. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - Antihypertensives (e.g., beta‑blockers): observe for enhanced blood pressure effects.